Portfolio
3
companies
Inivata
Inivata develops blood tests using circulating tumour DNA to improve cancer care.
Nuclera
Nuclera builds desktop bioprinters to accelerate protein expression and research workflows.
Zegami
Zegami provides visual data exploration software that helps businesses unlock insights from complex datasets.
The Cambridge biotechnology company has raised £31.4m from investors including M&G and Amadeus Capital Partners to advance its desktop protein printer.
"There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,"
The financing round was led by RT Capital Management alongside the Oxford Technology and Innovations EIS Fund.
"Over the last few years Zegami has been developing a cutting edge Visual Data Exploration platform to democratise data analytics, enabling people to make sense of the tsunami of data available today."
The financing round was led by RT Ventures and will support the US commercial roll-out of the company test.
"This Series B financing allows us to commercialize our lead product in patients with advanced lung cancer, following our positive reimbursement decision. We also have an exciting portfolio of future products that will be advanced in parallel to maximize the benefits of our industry-leading InVision Liquid Biopsy platform to patients. We are grateful to our existing investors for their continued support and are delighted to welcome RT Ventures to our already strong investor base. With these funds in place, we look forward to continuing our mission to transform the lives of cancer patients through the power of liquid biopsy."
